Intellia Therapeutics, Inc. reported earnings results for the full year ended December 31, 2023. For the full year, the company reported net loss was USD 481.19 million compared to USD 474.19 million a year ago. Basic loss per share from continuing operations was USD 5.42 compared to USD 6.16 a year ago.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
20.76 USD | +3.70% | -3.76% | -31.91% |
Apr. 15 | Intellia Therapeutics, Inc. Appoints Michael P. Dube as Principal Accounting Officer | CI |
Mar. 25 | Intellia Therapeutics Ends Development Agreement With Regeneron Pharmaceuticals | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-31.91% | 2B | |
+1.51% | 42.75B | |
+8.57% | 41.34B | |
+49.22% | 41.61B | |
-12.36% | 26.59B | |
+8.92% | 25.49B | |
-25.13% | 18.12B | |
+29.17% | 12.24B | |
-3.12% | 11.76B | |
+6.35% | 11B |
- Stock Market
- Equities
- NTLA Stock
- News Intellia Therapeutics, Inc.
- Intellia Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023